Outcome of Board Meeting - Submission of Unaudited Financial Results for the quarter ended on 30th September, 2025 and of Limited Review Report thereon
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Denis Chem Lab, a Gujarat-based manufacturer of parenteral (transfusion) products, reported weak Q2 FY26 numbers. Revenue from operations stood at Rs. 4,617.13 lakhs, down about 3.4% year-on-year from Rs. 4,781.76 lakhs. Profit after tax fell sharply to Rs. 221.25 lakhs (from Rs. 353.06 lakhs, a drop of around 37%), pulling EPS down to Rs. 1.60 from Rs. 2.54. For the first half, revenue was nearly flat at Rs. 8,944.72 lakhs but PAT declined around 16% to Rs. 468.75 lakhs. The auditor (Shah & Shah Associates) issued an unmodified review report with no qualifications. The company has no subsidiaries and operates in a single segment. Note: a 15% dividend (Rs. 1.50 per share, totalling Rs. 208.15 lakhs) was approved at the AGM on 26 September 2025.
Negative for the stock in the near term – shrinking revenue, a steep fall in profits, and a worrying Rs. 1,148 lakh build-up in trade receivables drove operating cash flow into the red (Rs. -83.94 lakhs for H1) and forced short-term borrowings to jump from Rs. 36.73 lakhs to Rs. 753.09 lakhs. Margin compression and working-capital strain are the key risks to track; the clean auditor report is a small positive.